Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations

Ann Lab Med. 2023 May 1;43(3):290-294. doi: 10.3343/alm.2023.43.3.290. Epub 2022 Dec 22.

Abstract

While numerous studies have evaluated humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, data on the cellular responses to these vaccines remain sparse. We evaluated T cell responses to ChAdOx1-nCoV-19 and BNT162b2 vaccinations using an interferon gamma (IFN-γ) release assay (IGRA). ChAdOx1-nCoV-19- and BNT162b2-vaccinated participants initially showed stronger T cell responses than unvaccinated controls. The T cell response decreased over time and increased substantially after the administration of a BNT162b2 booster dose. Changes in the T cell response were less significant than those in the anti-receptor-binding domain IgG antibody titer. The study results can serve as baseline data for T cell responses after SARS-CoV-2 vaccination and suggest that the IGRA can be useful in monitoring immunogenicity.

Keywords: Cellular responses; Humoral responses; Immunogenicity; Severe acute respiratory syndrome coronavirus 2; Vaccination.

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19*
  • Humans
  • SARS-CoV-2
  • Vaccination

Substances

  • ChAdOx1 nCoV-19
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • Antibodies, Viral